As spring unfolds across the Netherlands, a familiar seasonal challenge is intensifying for millions: hay fever season has arrived with unusual vigor, coinciding with concerning shortages of essential medications used to manage both allergic rhinitis and asthma symptoms. According to recent reporting from Dutch health authorities and pharmacy organizations, the convergence of early pollen surges and disrupted supply chains has left many patients struggling to access their usual treatments.
The situation has drawn attention from medical professionals who emphasize that while sneezing and itchy eyes are the most visible signs of hay fever, the condition can significantly impact respiratory health, particularly for those with underlying asthma. Dr. Helena Fischer, Editor of Health at World Today Journal, notes that effective management requires access to reliable medication options, especially when pollen counts spike unexpectedly due to unseasonably warm weather patterns.
Current shortages affect several commonly prescribed antihistamines, including levocetirizine, promethazine, acrivastine, and fexofenadine—medications often relied upon by individuals experiencing moderate to severe allergic reactions. At the same time, critical asthma inhalers such as salbutamol aerosol (100 µg, 200 doses) and the salbutamol/ipratropium combination nebulizer solution are also intermittently unavailable, creating compounded risks for patients whose allergies trigger bronchospasm or wheezing.
These supply issues are not isolated incidents but reflect broader vulnerabilities in pharmaceutical distribution networks. The Royal Dutch Pharmacists Association (KNMP) has reported that while salbutamol aerosol supplies are expected to normalize by the end of May 2026, the timeline for restoring the nebulizer solution remains uncertain. Meanwhile, data from the Pharmaceutical Key Figures Foundation (SFK) indicates a 9% decline in the dispensing of these two asthma-related medications at pharmacies, suggesting either reduced access or shifting prescribing patterns during the shortage period.
For patients navigating this landscape, healthcare providers recommend proactive steps: contacting multiple pharmacies to check availability, consulting with physicians about clinically appropriate alternatives, and—only under strict medical supervision—considering temporary import options from abroad where regulatory approval permits. Health insurers may assist by leveraging their supplier networks, but any medication change must be undertaken cautiously and in direct consultation with a treating physician to avoid adverse effects or loss of symptom control.
The underlying driver of heightened symptoms this year appears to be an exceptionally early and intense pollen season. Birch trees, along with early grass species, began blooming weeks ahead of schedule following a mild winter, rapidly elevating airborne allergen levels. The Leiden University Medical Centre (LUMC) estimates that approximately 20% of the Dutch population experiences some form of hay fever, ranging from mild discomfort to severe reactions that can exacerbate asthma.
This environmental-triggers-meets-supply-chain-strain scenario underscores the importance of preparedness for both individuals and healthcare systems. While no single solution exists, maintaining open communication between patients, pharmacists, and physicians remains the most reliable strategy for ensuring continuity of care during periods of medication uncertainty.
As of mid-April 2026, official updates on medication availability are being monitored through the KNMP and SFK channels. Patients are encouraged to verify current stock levels with their local pharmacy and seek personalized medical advice before making any changes to their treatment regimen.
Have you experienced difficulties accessing your usual allergy or asthma medication this spring? Share your experience in the comments below to support others navigate similar challenges, and consider sharing this article with anyone who might benefit from understanding the current landscape of hay fever and asthma care in the Netherlands.